We are live on
!
Find out more
ACM
Aquilo Capital Management Portfolio holdings
AUM
$55.8M
1-Year Est. Return
41.76%
This Fund
S&P 500
This Quarter
Est. Return
+20.54%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$180M
AUM Growth
-$60.8M
(-25%)
Cap. Flow
-$82.2M
Cap. Flow
% of AUM
-45.55%
Top 10 Holdings %
Top 10 Hldgs %
97.29%
Holding
15
New
3
Increased
2
Reduced
7
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
C4 Therapeutics
CCCC
|
+$2.44M |
| 2 |
Olema Pharmaceuticals
OLMA
|
+$1.51M |
| 3 |
Kymera Therapeutics
KYMR
|
+$1.43M |
| 4 |
Regenxbio
RGNX
|
+$753K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
uniQure
QURE
|
+$12.8M |
| 2 |
MRUS
Merus
MRUS
|
+$9.85M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
+$9.45M |
| 4 |
Arrowhead Research
ARWR
|
+$5.52M |
| 5 |
argenx
ARGX
|
+$3.02M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Arrowhead Research
ARWR
$12.4B
| $30.6M | 16.96% |
858,474
-160,000
| -16% | -$5.52M |
|
|
BPMC
2
DELISTED
Blueprint Medicines
BPMC
| $28.4M | 15.72% |
448,987
-173,842
| -28% | -$9.45M |
|
3
PUT
iShares Russell 2000 ETF
IWM
$81.9B
| $28.1M | 15.57% |
+150,000
| New | +$26.7M |
|
|
MRUS
4
DELISTED
Merus
MRUS
| $20.4M | 11.31% |
775,109
-450,000
| -37% | -$9.85M |
|
|
5
Regenxbio
RGNX
$708M
| $17.4M | 9.64% |
870,114
+39,100
| +5% | +$753K |
|
6
Arvinas
ARVN
$572M
| $15.5M | 8.58% |
623,941
-5,000
| -0.8% | -$129K |
|
|
7
Kymera Therapeutics
KYMR
$8.94B
| $15M | 8.3% |
651,325
+50,000
| +8% | +$1.43M |
|
|
SLN
8
Silence Therapeutics
SLN
$564M
| $7.22M | 4% |
1,312,233
| – | – |
|
9
Genmab
GMAB
$19.5B
| $6.64M | 3.68% |
174,648
-68,200
| -28% | -$2.72M |
|
|
10
argenx
ARGX
$54.1B
| $6.36M | 3.52% |
16,315
-7,685
| -32% | -$3.02M |
|
|
11
Olema Pharmaceuticals
OLMA
$1.05B
| $2.26M | 1.25% |
+250,000
| New | +$1.51M |
|
|
12
C4 Therapeutics
CCCC
$412M
| $2.09M | 1.16% |
+760,657
| New | +$2.44M |
|
|
PVLA
13
Palvella Therapeutics
PVLA
$2.27B
| $547K | 0.3% |
41,290
-15,621
| -27% | -$947K |
|
14
PUT
Invesco QQQ Trust
QQQ
$481B
| – | – |
-220,000
| Closed | -$70.6M |
|
|
15
uniQure
QURE
$3.22B
| – | – |
-637,526
| Closed | -$12.8M |
|
Similar funds
VCM
YEPV
HWP
GIS
AA
PGIM
RGMC
PAM
Aquilo Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Aquilo Capital Management held 15 positions worth $180M, down 25% from $241M the previous quarter. Its ten largest holdings account for 97% of the portfolio.
Aquilo Capital Management withdrew a net $82.2M in Q2 2023, closing 2 positions and reducing 7 holdings. Its most notable exit was uniQure, an estimated $12.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 71% a quarter earlier.
Against the trend, Aquilo Capital Management opened a new position in C4 Therapeutics worth $2.09M.
- Aquilo Capital Management's largest Q2 2023 buy was C4 Therapeutics: 760,657 shares worth $2.09M.
- Aquilo Capital Management added most to Kymera Therapeutics in Q2 2023, an estimated $1.43M increase.
- Aquilo Capital Management's biggest Q2 2023 reduction was Merus, cutting an estimated $9.85M.
- Aquilo Capital Management fully exited uniQure in Q2 2023, selling an estimated $12.8M.
- Aquilo Capital Management's ten largest holdings make up 97% of its $180M portfolio in Q2 2023.
- Aquilo Capital Management opened 3 new positions and closed 2 in Q2 2023.
- Aquilo Capital Management's portfolio value fell 25% quarter-over-quarter to $180M.
Based on Aquilo Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.